<DOC>
	<DOCNO>NCT00133705</DOCNO>
	<brief_summary>The purpose trial determine low-dose mifepristone benefit woman symptomatic fibroid .</brief_summary>
	<brief_title>Trial Mifepristone Fibroids</brief_title>
	<detailed_description>This trial design assess efficacy tolerability mifepristone 5 mg give daily 6 month pre-menopausal woman symptomatic fibroid . The primary study outcome disease-specific quality life . Secondary outcome measure include global quality life , pain , bleeding , potential adverse effect , tumor size , endometrial effect . The researcher also examine effect mifepristone uterine blood flow . Randomization study subject stratify order ensure equal number woman moderate severe symptom enrol placebo control group .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Gender : Female Age : 18 premenopausal Have least moderate symptom menorrhagia pelvic pain/pressure Have total uterine volume great equal 160 cc ultrasound measurement least one fibroid = &gt; 2.5cm size Have score equal great 39 Uterine Fibroid Symptom Quality Life scale Declined standard treatment option symptomatic fibroid Agree use doublebarrier method ( condom , diaphragm ) effective nonhormonal method contraception ( abstinence , sterilization ) throughout participation study prevent pregnancy report exposure pregnancy research staff immediately Willing able give inform consent Willing able comply study requirement Current plan pregnancy study period Menopausal , indicate follicle stimulate hormone ( FSH ) level reference laboratory Currently breastfeed Untreated abnormal pap smear Presence condition fibroids contribute pain and/or bleed Hemoglobin &lt; 9.0 mg/dl Presence adnexal mass tenderness indicate evaluation surgery Grade III IV hydronephrosis ultrasound Severe , active mental health disorder Active substance abuse dependence Presence contraindication mifepristone include : Adrenal insufficiency history Sickle cell disease Active liver disease ( liver function test great 1.5 time upper range normal ) Severe , respiratory disease ( P02 saturation &lt; 92 % ) Renal disease ( serum creatinine &gt; 1.5 mg/dl ) Blood clot defect . ( abnormal PT PTT ) Thromboembolic disease ( history deep vein thrombosis pulmonary embolus ) Current recent ( within past 3 month ) use follow medication : Oral systemic corticosteroid Hormones : estrogen , progestin , oral contraceptive Danazol , anticoagulants Herbal botanical supplement possible hormonal effect . Use within past six month gonadotropin release hormone ( GnRH ) analogs DepoProvera . Current plan use study follow medications/or product : ketoconazole , itraconazole , erythromycin , grapefruit juice , rifampin , St John 's Wort , phenytoin , phenobarbital , carbamazepine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>A benign tumor derive smooth uterine muscle tissue .</keyword>
</DOC>